Compare Stocks: AMLX, BMRN, MDGL, and KRYS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$27.68 +2.2%	$31.20	$10.83 ▼ $41.14	$3.08B	-0.1	1.63 million shs	411,458 shs
BMRN BioMarin Pharmaceutical	$55.72 -0.1%	$61.71	$49.26 ▼ $70.98	$10.79B	0.22	2.10 million shs	602,156 shs
KRYS Krystal Biotech	$315.65 +0.6%	$338.84	$183.26 ▼ $382.54	$9.35B	0.5	324,936 shs	52,331 shs
MDGL Madrigal Pharmaceuticals	$443.15 +1.2%	$506.16	$393.61 ▼ $615.00	$10.23B	-1.04	329,178 shs	64,585 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	-0.40%	-0.88%	-8.14%	+38.57%	+91.18%
BMRN BioMarin Pharmaceutical	-0.36%	+1.98%	-7.48%	-10.18%	+2.33%
KRYS Krystal Biotech	+0.69%	-2.06%	-9.30%	-13.88%	+68.52%
MDGL Madrigal Pharmaceuticals	+0.81%	-2.09%	-15.26%	-18.76%	+3.85%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$27.68 +2.2%	$31.20	$10.83 ▼ $41.14	$3.08B	-0.1	1.63 million shs	411,458 shs
BMRN BioMarin Pharmaceutical	$55.72 -0.1%	$61.71	$49.26 ▼ $70.98	$10.79B	0.22	2.10 million shs	602,156 shs
KRYS Krystal Biotech	$315.65 +0.6%	$338.84	$183.26 ▼ $382.54	$9.35B	0.5	324,936 shs	52,331 shs
MDGL Madrigal Pharmaceuticals	$443.15 +1.2%	$506.16	$393.61 ▼ $615.00	$10.23B	-1.04	329,178 shs	64,585 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	-0.40%	-0.88%	-8.14%	+38.57%	+91.18%
BMRN BioMarin Pharmaceutical	-0.36%	+1.98%	-7.48%	-10.18%	+2.33%
KRYS Krystal Biotech	+0.69%	-2.06%	-9.30%	-13.88%	+68.52%
MDGL Madrigal Pharmaceuticals	+0.81%	-2.09%	-15.26%	-18.76%	+3.85%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	2.89	Moderate Buy	$40.71	50.29% Upside
BMRN BioMarin Pharmaceutical	2.81	Moderate Buy	$88.60	58.92% Upside
KRYS Krystal Biotech	2.93	Moderate Buy	$377.20	20.26% Upside
MDGL Madrigal Pharmaceuticals	2.78	Moderate Buy	$699.20	59.73% Upside

Current Analyst Ratings Breakdown

Latest AMLX, BMRN, MDGL, and KRYS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/23/2026	KRYS Krystal Biotech	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Buy (B-) ➝ Buy (B)
10/23/2026	KRYS Krystal Biotech	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
10/21/2026	BMRN BioMarin Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$124.00 ➝ $122.00
10/20/2026	BMRN BioMarin Pharmaceutical	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$86.00 ➝ $87.00
10/20/2026	BMRN BioMarin Pharmaceutical	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$86.00
10/15/2026	MDGL Madrigal Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/15/2026	AMLX Amylyx Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$32.00 ➝ $39.00
10/15/2026	BMRN BioMarin Pharmaceutical	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$114.00 ➝ $88.00
10/15/2026	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$361.00
10/14/2026	MDGL Madrigal Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$735.00

(Data available from 10/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	$87.37M	34.55	N/A	N/A	$2.78 per share	9.74
BMRN BioMarin Pharmaceutical	$3.22B	3.35	$2.84 per share	19.61	$31.68 per share	1.76
KRYS Krystal Biotech	$440.48M	21.08	$7.34 per share	42.73	$42.06 per share	7.46
MDGL Madrigal Pharmaceuticals	$1.28B	7.88	N/A	N/A	$26.54 per share	16.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	-$144.74M	-$1.43	N/A	N/A	N/A	N/A	-52.92%	-48.53%	11/5/2026 (Estimated)
BMRN BioMarin Pharmaceutical	$348.90M	$0.37	150.68	10.50	0.61	2.14%	5.32%	3.69%	11/2/2026 (Estimated)
KRYS Krystal Biotech	$204.83M	$7.98	39.31	35.72	N/A	54.82%	19.34%	17.65%	11/2/2026 (Estimated)
MDGL Madrigal Pharmaceuticals	-$288.28M	-$12.89	N/A	82.59	N/A	-25.32%	-56.65%	-25.53%	11/3/2026 (Estimated)

Latest AMLX, BMRN, MDGL, and KRYS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	AMLX Amylyx Pharmaceuticals	-$0.3805	N/A	N/A	N/A	$0.06 million	N/A
11/3/2026	Q3 2026	MDGL Madrigal Pharmaceuticals	-$0.8629	N/A	N/A	N/A	$404.17 million	N/A
11/2/2026	Q3 2026	BMRN BioMarin Pharmaceutical	-$0.0886	N/A	N/A	N/A	$1.02 billion	N/A
11/2/2026	Q3 2026	KRYS Krystal Biotech	$1.82	N/A	N/A	N/A	$126.22 million	N/A
8/6/2026	Q2 2026	AMLX Amylyx Pharmaceuticals	-$0.3609	-$0.39	-$0.0291	-$0.39	N/A	N/A
8/6/2026	Q2 2026	BMRN BioMarin Pharmaceutical	$0.95	$1.20	+$0.25	$0.23	$932.03 million	$989.71 million
8/3/2026	Q2 2026	KRYS Krystal Biotech	$1.70	$1.79	+$0.09	$1.79	$120.93 million	$119.22 million
7/30/2026	Q2 2026	MDGL Madrigal Pharmaceuticals	-$2.68	-$1.99	+$0.69	-$1.99	$352.13 million	$364.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	12.12	12.12
BMRN BioMarin Pharmaceutical	0.56	2.39	1.32
KRYS Krystal Biotech	N/A	8.32	7.96
MDGL Madrigal Pharmaceuticals	0.65	3.20	2.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
BMRN BioMarin Pharmaceutical	98.71%
KRYS Krystal Biotech	86.29%
MDGL Madrigal Pharmaceuticals	98.50%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	10.90%
BMRN BioMarin Pharmaceutical	0.68%
KRYS Krystal Biotech	13.10%
MDGL Madrigal Pharmaceuticals	17.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	136	111.42 million	99.28 million	Optionable
BMRN BioMarin Pharmaceutical	3,221	193.57 million	192.26 million	Optionable
KRYS Krystal Biotech	295	29.60 million	25.72 million	Optionable
MDGL Madrigal Pharmaceuticals	915	23.10 million	19.04 million	Optionable

AMLX, BMRN, MDGL, and KRYS Headlines

Recent News About These Companies

Will Madrigal (MDGL) Report Negative Earnings Next Week? What You Should Know

1 hour ago | zacks.com

Madrigal Pharmaceuticals (MDGL) Expected to Announce Earnings on Tuesday

4 hours ago | marketbeat.com

Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH

4 hours ago | globenewswire.com

Critical Contrast: Madrigal Pharmaceuticals (NASDAQ:MDGL) & Incyte (NASDAQ:INCY)

October 25 at 4:29 AM | americanbankingnews.com

Madrigal Pharmaceuticals: The Market Is Grading A Launch, Not A Self-Funding Franchise

October 20, 2026 | seekingalpha.com

UBS raises target to USD 735 for Madrigal Pharmaceuticals stock

October 20, 2026 | ad-hoc-news.deA

Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026

October 20, 2026 | globenewswire.com

Madrigal Pharmaceuticals, Inc. $MDGL Stock Sold by Assenagon Asset Management S.A.

October 20, 2026 | marketbeat.com

Madrigal Pharmaceuticals, Inc. (MDGL) - What Are Investment Firms Thinking About This Stock?

October 20, 2026 | americanbankingnews.com

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock Has Average Target Price of $699.20 According to Analysts

October 20, 2026 | marketbeat.com

BofA Securities Adjusts Price Target on Madrigal Pharmaceuticals to $533 From $543, Maintains Neutral Rating

October 19, 2026 | marketscreener.comM

UBS raises target to USD 735.00 for Madrigal Pharmaceuticals stock

October 17, 2026 | ad-hoc-news.deA

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - October 15, 2026

October 16, 2026 | biospace.comB

UBS lifts target for Madrigal Pharmaceuticals stock to USD 735.00

October 15, 2026 | ad-hoc-news.deA

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

October 15, 2026 | globenewswire.com

Madrigal Pharmaceuticals, Inc. $MDGL Shares Newly Acquired by Sivik Global Healthcare LLC

October 13, 2026 | marketbeat.com

Analysts Are Bullish on These Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), Altimmune (ALT)

October 10, 2026 | theglobeandmail.com

Madrigal Pharmaceuticals (MDGL) Stock Trades At A Discount Following A Very Large 5 Year Run

October 8, 2026 | uk.finance.yahoo.com

Madrigal Pharmaceuticals (MDGL) Genetics Update Keeps Fair Value In Focus

October 8, 2026 | finance.yahoo.com

Is Rezdiffra’s Genetic-Risk Agnostic Data Reframing The Investment Case For Madrigal Pharmaceuticals (MDGL)?

October 7, 2026 | finance.yahoo.com

Madrigal Pharmaceuticals stock gets fresh Rezdiffra data

October 7, 2026 | ad-hoc-news.deA

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMLX, BMRN, MDGL, and KRYS Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$27.68 +0.59 (+2.16%)

As of 12:32 PM Eastern

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

BioMarin Pharmaceutical NASDAQ:BMRN

$55.72 -0.04 (-0.06%)

As of 12:32 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Krystal Biotech NASDAQ:KRYS

$315.64 +1.99 (+0.63%)

As of 12:31 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Madrigal Pharmaceuticals NASDAQ:MDGL

$443.15 +5.41 (+1.24%)

As of 12:32 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AMLX, BMRN, MDGL, and KRYS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AMLX, BMRN, MDGL, and KRYS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AMLX, BMRN, MDGL, and KRYS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMLX, BMRN, MDGL, and KRYS Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

BioMarin Pharmaceutical NASDAQ:BMRN

Krystal Biotech NASDAQ:KRYS

Madrigal Pharmaceuticals NASDAQ:MDGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AMLX, BMRN, MDGL, and KRYS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AMLX, BMRN, MDGL, and KRYS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AMLX, BMRN, MDGL, and KRYS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMLX, BMRN, MDGL, and KRYS Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

BioMarin Pharmaceutical NASDAQ:BMRN

Krystal Biotech NASDAQ:KRYS

Madrigal Pharmaceuticals NASDAQ:MDGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools